Trials / Completed
CompletedNCT02380196
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC). Patients scheduled to undergo surgical intervention will have blood samples obtained to test for CTCs. Presence of CTCs will be compared to final pathologic diagnosis based on surgical specimens to assess the sensitivity of using CTCs alone to make a definitive diagnosis.
Conditions
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2015-03-05
- Last updated
- 2020-04-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02380196. Inclusion in this directory is not an endorsement.